Free Trial

Provexis (PXS) Competitors

GBX 0.55
0.00 (0.00%)
(As of 11/1/2024 ET)

PXS vs. ALK, SHIP, CLCO, TORO, ICON, PAA, GEL, MMP, AAL, and GNK

Should you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Alkemy Capital Investments (ALK), Tufton Oceanic Assets (SHIP), CloudCoCo Group (CLCO), Chenavari Toro Income Fund (TORO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), and Greene King (GNK). These companies are all part of the "transportation" industry.

Provexis vs.

Provexis (LON:PXS) and Alkemy Capital Investments (LON:ALK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Provexis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Alkemy Capital Investments
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 0.00% beat Provexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Provexis-73.10% -138.67% -56.14%
Alkemy Capital Investments N/A N/A -258.00%

Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote.

CompanyUnderperformOutperform
ProvexisOutperform Votes
61
64.21%
Underperform Votes
34
35.79%
Alkemy Capital InvestmentsOutperform Votes
153
76.88%
Underperform Votes
46
23.12%

7.9% of Provexis shares are owned by institutional investors. Comparatively, 1.5% of Alkemy Capital Investments shares are owned by institutional investors. 21.6% of Provexis shares are owned by insiders. Comparatively, 43.7% of Alkemy Capital Investments shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Provexis has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Alkemy Capital Investments has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Provexis has higher revenue and earnings than Alkemy Capital Investments.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provexis£426.17K29.17N/AN/AN/A
Alkemy Capital InvestmentsN/AN/A-£1.77M-£0.23-495.65

In the previous week, Alkemy Capital Investments had 5 more articles in the media than Provexis. MarketBeat recorded 5 mentions for Alkemy Capital Investments and 0 mentions for Provexis. Alkemy Capital Investments' average media sentiment score of 0.41 beat Provexis' score of 0.00 indicating that Alkemy Capital Investments is being referred to more favorably in the news media.

Company Overall Sentiment
Provexis Neutral
Alkemy Capital Investments Neutral

Summary

Alkemy Capital Investments beats Provexis on 8 of the 12 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PXS vs. The Competition

MetricProvexisDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£12.43M£1.22B£5.40B£1.58B
Dividend Yield5.06%3.13%5.13%11.08%
P/E Ratio43.75110.73115.481,723.54
Price / Sales29.173,426.271,483.20228,959.04
Price / CashN/A10.1939.6535.69
Price / BookN/A3.174.662.87
Net IncomeN/A£155.16M£119.06M£144.80M
7 Day Performance-3.93%-0.02%0.80%0.11%
1 Month PerformanceN/A-0.70%5.66%-0.16%
1 Year Performance5.77%100.91%36.76%15.21%

Provexis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXS
Provexis
N/AGBX 0.55
flat
N/A+0.8%£12.43M£426,168.0043.754Gap Down
ALK
Alkemy Capital Investments
N/AGBX 114
+2.2%
N/A+1.4%£10.04MN/A-495.6525,500Gap Up
High Trading Volume
SHIP
Tufton Oceanic Assets
N/AGBX 1.28
-0.8%
N/A+32.0%£3.72M£39.75M10.6350
CLCO
CloudCoCo Group
N/AGBX 0.33
flat
N/A-72.0%£2.30M£27.31M-115.00125
TORO
Chenavari Toro Income Fund
N/AN/AN/A+20.5%£1.66MN/A-17.30N/ADividend Increase
Positive News
ICON
Iconic Labs
N/AN/AN/A+0.0%£586,000.00£600,855.00-15.003Gap Up
High Trading Volume
PAA
22532 (PAA.L)
N/AN/AN/AN/A£0.00N/A0.004,100Gap Up
High Trading Volume
GEL
Greka Engineering & Technology
N/AN/AN/AN/A£0.00N/A0.002,110News Coverage
MMP
Marwyn Management Partners
N/AN/AN/AN/A£0.00N/A0.001,660
AAL
Anglo American
1.2176 of 5 stars
GBX 2,396
-0.2%
GBX 2,715
+13.3%
+15.0%£28.99B£29.44B-2,303.85129,700News Coverage
GNK
Greene King
N/AN/AN/A+0.0%£2.63B£2.22B21.941,010News Coverage
High Trading Volume

Related Companies and Tools


This page (LON:PXS) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners